2017 Fiscal Year Final Research Report
Development of nucleic acid therapy using rapid acting DDS
| Project/Area Number |
15H04920
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
森 正樹 大阪大学, 医学系研究科, 教授 (70190999)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | ドラッグデリバリーシステム / 核酸医療 |
|---|
| Outline of Final Research Achievements |
Super carbonate apatite particles incorporating miR-29b-1-5p was effective to pancreatic cancer cells, while miR-4689 was not so effective to pancreatic cancer cells. sCA could lower interstitial fluid pressure (IFP) at the tumor stroma via integrin mediated mechanism. EPR related molecules hydroxyperoxidase, TNF α, nicotine were also affected. This led to efficient accumulation of anti-tumor agents or light sensitizer ICG in the tumor tissues by sCA injection alone. sCA-ICG is thought to be a good candidate for the photodynamic therapy. PEGylation of sCA did not realize improvement of stealth effect or increased tumor uptake. Finally we could make up a novel DDS device that does not accumulate in liver, yet does accumulate abundantly in tumor only with 10% amount of nucleic acid when compared to sCA. This would facilitate nucleic acid medicine in near future.
|
| Free Research Field |
消化器外科学
|
